All In Biotech

Drug Trial Radar · NCT04299633

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

A Phase 1, Three-Part, Open-Label Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Last checked: Nov 20, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Jun 15, 2020

Primary completion

Aug 2, 2020

Study completion Sep 28, 2020

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This 3-part study will be conducted to evaluate the interaction of vadadustat with sevelamer carbonate, calcium acetate, and Auryxia in healthy male and female participants. A total of 18 participants will be enrolled in each part of the study. Part 1 of the study will be conducted to assess the effect of a single oral dose of sevelamer carbonate (1600 milligrams \[mg\]) on the pharmacokinetics (PK) of a single oral dose of vadadustat (300 mg). Part 2 of the study will be conducted to assess the effect of a single oral dose of calcium acetate (1334 mg) on the PK of a single oral dose of vadadustat (300 mg). Part 3 of the study will be conducted to assess the effect of a single oral dose of Auryxia® (2 grams) on the PK of a single oral dose of vadadustat (300 mg).

Conditions

  • Healthy Volunteers

Interventions

  • VadadustatDrug

    2 x 150 mg oral tablets

  • Sevelamer carbonateDrug

    2 x 800 mg oral tablets

  • Calcium acetateDrug

    2 x 667 mg oral gelcaps

  • Auryxia®Drug

    2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vadadustat area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part
  2. Vadadustat area under the plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part
  3. Maximum observed plasma concentration (Cmax) of vadadustatTime frame: 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, and 48 hours after each dose of vadadustat in each 9-day study part

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Québec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.